Featured Publications
Subcellular progression of mesenchymal transition identified by two discrete synchronous cell lines derived from the same glioblastoma
Kim S, Park S, Chowdhury T, Hong J, Ahn J, Jeong T, Yu H, Shin Y, Ku J, Park J, Hur J, Lee H, Kim K, Park C. Subcellular progression of mesenchymal transition identified by two discrete synchronous cell lines derived from the same glioblastoma. Cellular And Molecular Life Sciences 2022, 79: 181. PMID: 35278143, PMCID: PMC8918182, DOI: 10.1007/s00018-022-04188-3.Peer-Reviewed Original ResearchConceptsMesenchymal transitionCell linesAvailable single-cell RNA-seq dataMesenchymal transition (EMT) processCancer cell linesSame tissue samplesTherapeutic implicationsTumor samplesRecurrent samplesDriver mutationsGlioblastomaTissue samplesDistinct cancer cell linesGBM samplesIntratumoral heterogeneityTranscriptomic characteristics
2023
Patient-derived glioblastoma cell lines with conserved genome profiles of the original tissue
Kim S, Cho Y, Shin Y, Yu H, Chowdhury T, Kim S, Yi K, Choi C, Cha S, Park C, Ku J. Patient-derived glioblastoma cell lines with conserved genome profiles of the original tissue. Scientific Data 2023, 10: 448. PMID: 37438387, PMCID: PMC10338444, DOI: 10.1038/s41597-023-02365-y.Peer-Reviewed Original ResearchConceptsCell linesPatient-derived glioblastoma cell linesPatient-derived cell linesWhole exome sequencing datasetsExome sequencing datasetsGBM cell linesGlioblastoma cell linesSequence dataGenomic featuresLethal intracranial tumorSequencing technologiesSequencing datasetsMolecular markersWES datasetsGenome profilesMutational signaturesDruggable targetsNumber alterationsBiological credibilityGenomic profilesBiological platformMolecular characteristicsOriginal tissueTumor tissueGlioblastoma
2021
A Deep Dive: SIWV Tetra-Peptide Enhancing the Penetration of Nanotherapeutics into the Glioblastoma
Kang R, Park J, Kim J, Chowdhury T, Oh J, Kim J, Shin J, Kim M, Park C, Lee S, Lee J, Kim D. A Deep Dive: SIWV Tetra-Peptide Enhancing the Penetration of Nanotherapeutics into the Glioblastoma. ACS Biomaterials Science & Engineering 2021, 8: 4163-4174. PMID: 34196517, DOI: 10.1021/acsbiomaterials.1c00653.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCell Line, TumorGlioblastomaHumansMicePeptidesPolyethylene GlycolsSiliconSugarsTemozolomideConceptsDrug delivery systemsNanoparticle-based drug delivery systemsPolyethylene glycolHigher anticancer efficacyPorous silicon nanoparticlesDevelopment of nanotherapeuticsGlioblastoma multiformeSilicon nanoparticlesTetra peptideIRGD peptideTargeting abilityDelivery systemAnticancer efficacyNanoparticlesTherapeutic formulationsGreat promiseAggressive malignant tumorSite targetingNanotherapeuticsCell spheroidsPenetration abilityStructure specificityMalignant tumorsPenetration depthXenograft mice
2020
Inhibition of MUC1 exerts cell-cycle arrest and telomerase suppression in glioblastoma cells
Kim S, Seo Y, Chowdhury T, Yu H, Lee C, Kim K, Kang H, Kim H, Park S, Kim K, Park C. Inhibition of MUC1 exerts cell-cycle arrest and telomerase suppression in glioblastoma cells. Scientific Reports 2020, 10: 18238. PMID: 33106534, PMCID: PMC7589558, DOI: 10.1038/s41598-020-75457-z.Peer-Reviewed Original ResearchConceptsRole of MUC1Epithelial-mesenchymal transitionMucin 1Cell cycle arrestMUC1 knockdownNormal brain tissueExpression levelsGrowth factor betaTERT expression levelsGBM cell linesOverall survivalTherapeutic targetOncological processHuman gliomasBrain tissueFactor betaMesenchymal transitionPhosphorylation of RB1Diverse cancersGlioblastomaTelomere maintenance mechanismAnticancer mechanismCell proliferationCycle arrestGlioblastoma cells
2017
Glutaminase 2 expression is associated with regional heterogeneity of 5-aminolevulinic acid fluorescence in glioblastoma
Kim S, Kim J, Kim Y, Hwang T, Kim S, Xu W, Shin J, Kim J, Choi H, Kim H, Cho H, Choi A, Chowdhury T, Seo Y, Dho Y, Kim J, Kim D, Park S, Kim H, Choi S, Park S, Lee S, Park C. Glutaminase 2 expression is associated with regional heterogeneity of 5-aminolevulinic acid fluorescence in glioblastoma. Scientific Reports 2017, 7: 12221. PMID: 28939850, PMCID: PMC5610329, DOI: 10.1038/s41598-017-12557-3.Peer-Reviewed Original ResearchConceptsGlutaminase 2Subsequent metabolite profilingInsufficient NADPHKey genesRNA sequencingExpression profilingGene expressionFunctional analysisGenesExpression levelsMetabolite profilingGBM tissuesFluorescence heterogeneityMetabolic mechanismsNADPH production capacityFluorescence intensityAcid fluorescenceProfilingExpressionGlioblastoma treatmentProtoporphyrin IXFluorescenceIntratumoral heterogeneityFluorescence-guided surgeryTissue